ESLA קצב צמיחת רווח למניה בשנה הנוכחית Estrella Immunopharma Corp

ESLA (estrellabio.com) - סמל מסחרי של החברה

The absence of market sales and research expenditures are driving a steady cash burn, as confirmed by the year-over-year percentage change in EPS, where the figure is recorded at 0.00. The success of Estrella Immunopharma (ESLA) relies on the innovative ARTEMIS system for combating oncohematology; however, future growth depends on test safety and the ability to attract investment to expand clinical trials.

ESLA - צמיחת רווחים בשנה הנוכחית Estrella Immunopharma בטווח 21.02.2024 - 16.11.2026

פילוחי מדדים מקיפים ואנליטיקה עבור Estrella Immunopharma (ESLA)

- שווי מניות ותחזית קונצנזוס למחירים:
ניתוח בסיסי של החברה:Estrella Bio (ESLA)
מוצר סדרתי של Estrella Immunopharma Corp

Estrella Immunopharma (ESLA) is scaling the serial production of drugs thanks to the full readiness of partner plants and the calibration of laboratories. This indicator captures the percentage deviation of current earnings per share from last year's figures. Investors use this metric to verify the market value of the business relative to its actual profitability. Positive dynamics confirm the effectiveness of immunotherapeutic developments. By analyzing the history of annual changes in earnings per share, one can assess the company's resilience to industry risks.